FOXO4-DRI
A first-generation senolytic peptide engineered to selectively destroy senescent "zombie" cells by disrupting the FOXO4-p53 interaction that keeps them alive.
FOXO4-DRI is a synthetic 34-amino-acid D-retro-inverso peptide developed by Peter de Keizer's laboratory at Erasmus Medical Center to disrupt the protein-protein interaction between the FOXO4 transcription factor and p53 in senescent cells. In senescent cells, FOXO4 sequesters p53 in the nucleus and prevents apoptosis; FOXO4-DRI competitively frees p53, allowing it to relocate to the mitochondria and trigger selective cell death while sparing healthy neighbors. A landmark 2017 Cell study showed it reduced senescent cell burden and restored fitness, fur density, and renal function in aged mice, but there are no published human clinical trials and it remains a research-use-only compound with no regulatory approval.
Class
Synthetic 34-amino-acid D-retro-inverso senolytic peptide
Half-life
Not characterized in humans; the D-retro-inverso construction provides protease resistance that extends half-life from minutes to hours relative to L-peptides of similar size.
Routes
Subcutaneous, Intravenous
Category
Longevity & Bioregulators
Researched benefits
What it's studied for
Selective senescent cell clearance
FOXO4-DRI's defining action is senolysis: it triggers apoptosis specifically in senescent cells by releasing p53 from FOXO4 sequestration. In mixed cell cultures it kills the senescent fraction while leaving non-senescent fibroblasts largely intact (Baar et al., 2017).
Reduced tissue senescence burden
In naturally aged and chemotherapy-treated mice, dosing lowered markers of senescence (SA-beta-gal staining, p16 and p21 expression, SASP factors) across kidney, liver, muscle, and fur follicles, supporting the model that senescent-cell elimination mediates its organismal effects.
Restored organ and renal function
Aged mice showed improved renal function on creatinine and other markers after treatment, tracking with reductions in tissue senescence burden.
Improved fitness and phenotypic aging markers
Treated aged mice regained fur density, grooming behavior, and exploratory/activity levels; improvements were modest in absolute terms but consistent and mechanism-appropriate.
Reduced chronic inflammation (inflammaging)
Clearing senescent cells removes the local senescence-associated secretory phenotype (SASP) burden of pro-inflammatory cytokines, allowing neighboring cells and tissue stem cells to recover function and lowering systemic markers of age-related inflammation.
Potential neurological/cognitive applications
A 2026 review proposes that targeting the FOXO4-p53 axis clears senescent cells in the brain while preserving healthy tissue, with animal-model signals for restored blood-brain barrier integrity, cerebral blood flow, and cognitive function; this remains an emerging, review-level hypothesis.
Mechanism
How it works
FOXO4-DRI disrupts the protein-protein interaction between FOXO4 (Forkhead box O4) and the tumor suppressor p53 inside senescent cells. Senescent cells carry high baseline p53 (driven by DNA damage and oncogenic signaling) and accumulated pro-apoptotic mitochondrial priming, yet survive because FOXO4 continuously sequesters p53 in nuclear foci, keeping it away from the mitochondria. By competing with endogenous FOXO4 for p53 binding, FOXO4-DRI releases p53, which translocates to the mitochondrial outer membrane and activates the intrinsic apoptosis pathway.
At the mitochondria, freed p53 engages anti-apoptotic Bcl-2 family proteins (Bcl-XL, Bcl-2) and promotes Bax/Bak activation, causing outer mitochondrial membrane permeabilization, cytochrome c release, caspase activation, and apoptosis. Selectivity for senescent cells arises because non-senescent cells express FOXO4 and p53 at lower levels and lack the mitochondrial priming that makes p53 release lethal, so they are spared, the defining requirement of a useful senolytic.
The peptide is built as a D-retro-inverso (DRI) isomer, meaning it uses D-amino acids in reversed sequence relative to the native FOXO4 region that contacts p53. This construction recapitulates the three-dimensional binding surface while adding two practical advantages: protease resistance (human proteases cannot cleave D-amino acid bonds, extending half-life from minutes to hours) and cell permeability that allows it to cross plasma membranes without a specialized delivery system.
Downstream, removal of senescent cells lowers the paracrine SASP burden, permitting neighboring cells and tissue stem cells to resume normal function and reducing systemic inflammaging. Important limitations exist: not all senescent cells depend on FOXO4-p53 sequestration for survival, so the peptide may be less effective against senescence driven by other anti-apoptotic mechanisms, and its selectivity, tissue penetration (including across the blood-brain barrier), and behavior at higher doses are not fully characterized, particularly in humans.
Dosing protocols
Dosing & administration
Dosing reflects protocols reported in research and community literature for educational purposes. It is not medical advice or a recommendation. Most peptides here are not approved for human use.
Reconstitution
Supplied as lyophilized white-to-off-white powder in sealed vials of 5, 10, or 20 mg. Bring the vial to room temperature (10-15 minutes, never heat artificially). Reconstitute with bacteriostatic water (0.9% benzyl alcohol preserved); a common approach is 2 mL added to a 10 mg vial for a 5 mg/mL solution. Inject the water slowly down the vial wall rather than onto the powder, swirl gently (do not shake), and let it clarify. At 5 mg/mL on a U-100 insulin syringe: 20 units = 1 mg, 40 units = 2 mg, 100 units = 5 mg. Refrigerate reconstituted solution and use within roughly 2-4 weeks; discard if cloudy, discolored, or containing particulates.
Beginner
- Dose
- 2-5 mg per dose (most commonly 5 mg)
- Frequency
- Once daily for 3-5 consecutive days
- Timing
- Morning injections, spaced roughly 24 hours apart
- Duration
- One pulsed cycle, repeated no sooner than every 2-6 months
- Route
- Subcutaneous
Doses are extrapolated from rodent studies and vendor recommendations, not human PK data. Run baseline and 2-4 week post-cycle labs (CMP, CBC, LFTs) and track subjective symptoms; many users report transient flu-like symptoms during and after the dosing window.
Intermediate
- Dose
- 5-10 mg per dose
- Frequency
- Daily for 3-7 consecutive days
- Timing
- Morning injections, roughly 24 hours apart
- Duration
- One pulsed cycle every 3-6 months
- Route
- Subcutaneous
For those who have completed multiple beginner cycles without adverse effects. Some rotate (never same-day stack) with fisetin or physician-supervised dasatinib-quercetin between cycles. Expand monitoring to include inflammatory markers (hs-CRP), HbA1c, lipid/ApoB, and condition-specific markers.
Advanced
- Dose
- 10-15 mg per dose
- Frequency
- Daily for 5-10 consecutive days
- Timing
- Morning injections, roughly 24 hours apart
- Duration
- One pulsed cycle every 2-4 months
- Route
- Subcutaneous
Used by experienced self-experimenters with robust clinical monitoring. There is no clinical evidence that higher doses or more frequent cycles improve outcomes; they mainly increase cumulative exposure and cost. Extensive quarterly labs, senescence/biological-age testing, and imaging are advised.
- Dosing is pulsed, not continuous: senescent cells are thought to require episodic clearance, and animal-model timescales suggest months to a year for meaningful re-accumulation. Total annual cycles typically range from 1-4.
- Subcutaneous injection (28-31 gauge insulin syringe into abdominal fat, thigh, or upper arm) is the standard and safest self-administration route. Intravenous use is reported but carries added risks (infection, vascular injury, bolus reactions) and is not appropriate outside clinical supervision.
- Oral dosing is not expected to work: a 34-amino-acid peptide is poorly absorbed and carriers/linkers may still be degraded in the gut despite the D-amino acid backbone.
- Body-weight adjustment is generally not done in self-administered protocols; if scaled, typical doses map to roughly 0.05-0.15 mg/kg per dose. Rodent-derived body-surface-area scaling has no clinical validation in humans.
- Store lyophilized powder frozen (stable 1-2 years); refrigerate and use reconstituted solution within 2-4 weeks. Vendor quality varies widely, so third-party HPLC/mass-spec verification and certificates of analysis matter, especially given the complex D-retro-inverso structure.
- A defensible senolytic program does not begin with FOXO4-DRI, which has zero human clinical data; more evidence-supported options (fisetin, physician-supervised dasatinib-quercetin) exist. Clinical oversight is considered a baseline requirement given the risk profile.
Evidence
Research & clinical studies (3)
Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis in Response to Chemotoxicity and Aging
This landmark study (Baar et al.) demonstrated that FOXO4-DRI, a rationally designed peptide disrupting the FOXO4-p53 interaction, induced selective apoptosis of senescent cells in aged mice, restoring physical fitness, fur density, and renal function while sparing non-senescent cells, establishing proof-of-concept for peptide-based senolytic therapy.
PMID 28340339Rational design of a peptide inducing selective apoptosis of p53-high senescent cells by targeting the FOXO4-TP53 protein-protein interaction
Applying rational peptide-design principles to the FOXO4-TP53 interface produced the ES2 senolytic variant, which selectively cleared p53-high senescent cancer and aged liver cells in mouse models while leaving non-senescent cells intact, extending the therapeutic framework established for FOXO4-DRI.
PMID 34689087Targeting the FOXO4-p53 axis by retro-inverso peptide senolytic agents: a pharmacological strategy to mitigate brain aging and cognitive decline
This review argues that FOXO4-DRI-type senolytic peptides selectively eliminate senescent cells in the brain while preserving healthy tissue, with animal-model evidence for restored blood-brain barrier integrity, cerebral blood flow, and cognitive function, positioning FOXO4-p53 targeting as a potential strategy against age-related cognitive decline.
PMID 42024235Combinations
Stacking & blends
Rotating senolytic protocol
Broader senescent-cell coverage across cell subtypes
Different senolytics target different anti-apoptotic vulnerabilities, so some users rotate them across separate cycles (never same-day) on the theory that each clears a different subset of senescent cells. Fisetin and physician-supervised dasatinib-quercetin carry actual early human data; FOXO4-DRI does not. Clinical evidence for the combination approach is absent.
Comprehensive longevity stack
Multi-mechanism anti-aging coverage
FOXO4-DRI (senolytic) is listed as compatible or synergistic with Epithalon (telomere/epigenetic support), NAD+ (cellular energy/DNA repair), and fisetin (senolytic) in interaction matrices. Attribution of any effect to a specific component is impossible in practice, and these combinations have essentially no clinical validation.
Safety
Side effects & considerations
Commonly reported effects
Contraindications & cautions
- Active cancer, recent cancer treatment (within 12 months), or active cancer surveillance without explicit oncology supervision
- Pregnancy, breastfeeding, and attempts to conceive (absolute)
- Children and adolescents
- Active acute infection (relative; wait for resolution)
- Recent major surgery or significant injury (avoid for at least 4-6 weeks)
- Organ transplant recipients on immunosuppression
- Autoimmune disease on immunomodulatory therapy (relative)
- Significant cardiovascular, hepatic, or renal impairment, or unstable/uncontrolled diabetes (relative)
- Known hypersensitivity to peptide products or preparation components including bacteriostatic water preservative (absolute)
Human safety data is essentially absent, no published Phase 1 or later trials exist. Preclinical rodent studies did not surface significant toxicity at researched doses, but the senolytic mechanism raises theoretical concerns about effects on non-senescent stem cells and immune function, and long-term human safety is completely unknown. Reported post-dose flu-like symptoms may reflect genuine senescent-cell clearance (SASP/cellular contents released into circulation) or pyrogen/endotoxin contamination in research-chemical supply, which is difficult to distinguish without batch analytical testing. Drug-drug interactions are uncharacterized; theoretical concerns include chemotherapy, corticosteroids, immunosuppressants, anti-apoptotic drugs (navitoclax, venetoclax), mTOR inhibitors, metformin, and other senolytics. The absence of clinical oversight is itself considered a key safety gap for a compound with this risk profile.
FAQ
FOXO4-DRI — common questions
What does FOXO4-DRI actually do at the cellular level?
It is a D-retro-inverso peptide that disrupts the FOXO4-p53 interaction in senescent cells. In those cells the interaction sequesters p53 away from mitochondria and prevents apoptosis; disrupting it releases p53 to relocate to mitochondria and trigger cell death. Non-senescent cells lack the accumulated mitochondrial priming that makes p53 release lethal, so they are spared, producing selective killing of senescent cells.
Has FOXO4-DRI been tested in humans?
No. As of 2026, no Phase 1 or later human clinical trials have been published, no IND applications have been publicly disclosed, and no registered trials appear on ClinicalTrials.gov. All human use is self-experimentation with research-chemical vendor supply, and the senolytic mechanism remains hypothesis-driven at the human level.
What did the original Baar et al. 2017 study show?
The Cell paper showed FOXO4-DRI selectively killed senescent cells in culture, reduced senescent-cell burden in doxorubicin-treated mice with improved tissue function, and in naturally aged mice improved fur density, renal function, and activity levels. The improvements were modest in absolute terms, the aged mice did not become young, but they were consistent and mechanism-appropriate.
How is it different from other senolytics like fisetin or dasatinib+quercetin?
Different senolytics target different vulnerabilities of senescent cells. Dasatinib-quercetin affects SRC/TYK-family kinases and Bcl-XL, navitoclax (ABT-263) targets Bcl-2/Bcl-XL, and fisetin acts through multiple mechanisms including Bcl-XL inhibition. FOXO4-DRI specifically disrupts FOXO4-p53 sequestration, which is why some researchers advocate rotating or combining senolytics for broader coverage.
What dose of FOXO4-DRI do people use?
Self-report communities describe 2-15 mg per dose subcutaneously, with about 5 mg as a standard dose, given for 3-7 consecutive days in a pulsed cycle repeated every 2-6 months. These doses are extrapolated from rodent studies using body-surface-area scaling and have no clinical validation in humans.
Why do some people report flu-like symptoms after dosing?
Flu-like symptoms in the 24-72 hours after dosing may reflect actual senescent-cell clearance releasing SASP cytokines and cellular contents into circulation, or they may reflect pyrogen/endotoxin contamination in research-chemical supply. Distinguishing the two without batch-specific analytical testing is difficult, which is one reason high-quality vendor selection matters.
Is FOXO4-DRI safe for people with a cancer history?
It should not be used by people with active cancer, recently treated cancer (within 12 months), or active cancer surveillance without explicit oncology consultation. Senescence serves both tumor-suppressor and tumor-promoter roles depending on context, and the net effect of senolytic therapy on human cancer risk is unknown, so conservative avoidance is warranted.
What is the bottom line on whether it works in humans?
Unknown. The preclinical evidence is mechanistically compelling, but with no human clinical trials, efficacy in humans cannot be claimed. FOXO4-DRI sits in the intriguing-but-unvalidated category; for people interested in senolytic therapy, fisetin and physician-supervised dasatinib-quercetin are the options with actual human data.
